Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
Femasys Inc. announced that the U.S. FDA has approved a modular premarket approval (PMA) submission approach for FemBloc, their investigational non-surgical permanent birth control device. This approval accelerates the regulatory review process, supporting FemBloc's advancement toward U.S. market approval. FemBloc has been previously approved in Eu…